NCT02903836

Phase II Study of Oral Nafithromycin in CABP

A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 231 (actual)
• Sponsor: Wockhardt · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults

Conditions

• Community-Acquired Bacterial Pneumonia (CABP)

Interventions

Type	Name	Description
DRUG	Nafithromycin 800 mg 3 days
DRUG	Nafithromycin 800 mg 5 days
DRUG	Moxifloxacin 400 mg

Timeline

• Start date: 2016-11-18
• Primary completion: 2017-07-01
• Completion: 2017-07-08
• First posted: 2016-09-16
• Last updated: 2019-12-20
• Results posted: 2019-12-20

Locations

6 sites across 1 country: United States